An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric CancerOA
Background:Gastric cancer(GC)continues to pose a significant global health challenge due to its high rates of incidence and mortality,with the majority of cases identified at advanced stages.Immunotherapy,particularly immune checkpoint blockades(ICBs),has demonstrated considerable therapeutic potential;however,many patients do not exhibit a favorable response.As a result,constructing a predictive model to assess ICBs''responsiveness is essential for enhancing treatment outcomes.Methods:Using consensus clustering based on anoikis-related gene expression,GC patients were stratified into two subclusters.Differences in tumor immune microenvironment,ICB resistance,genomic alterations,methylation profiles,and transcriptional networks were analyzed.A machine learning-based strategy was employed to develop a consensus anoikis-related gene signature(ARGS).Potential therapeutic targets were identified through single-cell RNA sequencing(scRNA-seq),and validation was conducted using multiplex immunofluorescence and immunohistochemistry in an in-house cohort(n=28),including 14 ICB responders and 14 nonresponders.Results:The anoikis-resistant cluster(Cluster A)was associated with poorer survival,immunosuppressive infiltration,lower tumor mutation burden,and ICB resistance.ScRNA-seq revealed high fibroblast and endothelial infiltration,with GLI3+cancer-associated fibroblasts suggesting Hedgehog pathway involvement.The ARGS model effectively stratified patients,with elevated scores associ-ated with immunotherapy resistance,enhanced AR characteristics,and poorer clinical outcomes.
Xing Cai;Jinru Yang;Fangyuan Zhang;Fuwang Xu;Yuan Fang;Zongbi Yi
Department of Radiation and Medical Oncology,Hubei Key Laboratory of Tumor Biological Behaviors,Hubei Cancer Clinical Study Center,Zhongnan Hospital of Wuhan University,Wuhan,China Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,ChinaDepartment of Radiation and Medical Oncology,Hubei Key Laboratory of Tumor Biological Behaviors,Hubei Cancer Clinical Study Center,Zhongnan Hospital of Wuhan University,Wuhan,ChinaDepartment of Oncology,Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,ChinaThe Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,ChinaDepartment of Thyroid&Mammary Gland Surgery,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,ChinaDepartment of Radiation and Medical Oncology,Hubei Key Laboratory of Tumor Biological Behaviors,Hubei Cancer Clinical Study Center,Zhongnan Hospital of Wuhan University,Wuhan,China
医药卫生
anoikisgastric cancerimmune checkpoint blockadespredictive signaturesingle-cell RNA sequencing
《Cancer Innovation》 2026 (1)
P.47-63,17
National Science and Technology Major Project,Grant/Award Number:2024ZD0533300Excellent Doctor Program of Zhongnan Hospital of Wuhan University,Grant/Award Number:ZNYB2021009。
评论